Indication

T-Cell Acute Lymphoblastic Lymphoma

1 clinical trial

1 product

Clinical trial

Phase I Trial of Targeted Immunotherapy With Daratumumab Following Myeloablative TBI-Based Conditioning and AlloHCT in Children, Adolescents and Young Adults With High Risk T-Cell Acute Lymphoblastic Leukemia and Lymphoma (ALLO-T-DART)

Status: Recruiting, Estimated PCD: 2027-09-01

Product